Cargando…
Phosphodiesterase type-5 inhibitor use in type 2 diabetes is associated with a reduction in all-cause mortality
OBJECTIVE: Experimental evidence has shown potential cardioprotective actions of phosphodiesterase type-5 inhibitors (PDE5is). We investigated whether PDE5i use in patients with type 2 diabetes, with high-attendant cardiovascular risk, was associated with altered mortality in a retrospective cohort...
Autores principales: | Anderson, Simon G, Hutchings, David C, Woodward, Mark, Rahimi, Kazem, Rutter, Martin K, Kirby, Mike, Hackett, Geoff, Trafford, Andrew W, Heald, Adrian H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099221/ https://www.ncbi.nlm.nih.gov/pubmed/27465053 http://dx.doi.org/10.1136/heartjnl-2015-309223 |
Ejemplares similares
-
Cardiovascular and type 2 diabetes morbidity and all-cause mortality among diverse chronic inflammatory disorders
por: Dregan, Alex, et al.
Publicado: (2017) -
Antihypertensive drug effects on long-term blood pressure: an individual-level data meta-analysis of randomised clinical trials
por: Canoy, Dexter, et al.
Publicado: (2022) -
Prevalence and determinants of hypertension control among almost 100 000 treated adults in the UK
por: Tapela, Neo, et al.
Publicado: (2021) -
Systolic blood pressure, chronic obstructive pulmonary disease and cardiovascular risk
por: Rao, Shishir, et al.
Publicado: (2023) -
B-type natriuretic peptide-guided therapy for perioperative medicine?
por: Shang, Charles
Publicado: (2014)